MAPK3 and colorectal carcinoma: In agreement, Perkins et al. [49] observed no significant difference in phospho‐ERK1/2 and phospho‐Akt levels between KRAS WT (n = 23) and mutant (n = 19) CRC tumors, but there was no comparison with mucosa.